This Biotech Is Targeting Indications Worth $70 Billion

Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. ZVSA was recently a guest on Benzinga’s All-Access.

ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop transformative drugs for underserved patients with renal and inflammatory diseases. The company is currently advancing a therapeutic pipeline with multiple programs built around its two proprietary technologies – VAR 200 and IC 100.

The technologies could represent a leap forward in the treatment of several diseases.

Watch the full interview here: 

Featured photo by Hans Reniers on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.